{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T02:23:48Z","timestamp":1682648628995},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T00:00:00Z","timestamp":1462233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T00:00:00Z","timestamp":1462233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human immunodeficiency virus (HIV)-1 integrase (IN), which mediates integration of viral cDNA into the cellular chromosome, is a validated antiviral drug target. Three IN inhibitors, raltegravir, elvitegravir and dolutegravir, have been clinically approved since 2008. However, drug resistance have emerged in infected patients receiving treatment using these drugs which share the same mechanism of action and have a low genetic barrier for resistance. Therefore, there is an urgent need to develop drugs with novel mechanism. IN requires a precise and dynamic equilibrium between several oligomeric species for its activities. The modulation of the process which is termed as IN oligomerization, presents an interesting allosteric target for drug development. In this research, we developed a magnetic beads based approach to assay the IN dimerization. Then, using the assay we screened a library of 1000 Food and Drug Administration (FDA)-approved drugs for IN dimerization inhibitors and identified dexlansoprazole as a potential IN dimerization inhibitor. In conclusion, the assay presented here has been proven to be sensitive and specific for the detection of IN dimerization as well as for the identification of antiviral drugs targeting IN dimerization. Moreover, a FDA-approved proton-pump inhibitors, dexlansoprazole, was identified as a potential inhibitor for IN dimerization.<\/jats:p>","DOI":"10.1038\/srep25375","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T09:29:32Z","timestamp":1462267772000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A novel assay for screening inhibitors targeting HIV-1 integrase dimerization based on Ni-NTA magnetic agarose beads"],"prefix":"10.1038","volume":"6","author":[{"given":"Dawei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqiu","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengmeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixia","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunxing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,3]]},"reference":[{"key":"BFsrep25375_CR1","doi-asserted-by":"publisher","first-page":"a006890","DOI":"10.1101\/cshperspect.a006890","volume":"2","author":"R Craigie","year":"2012","unstructured":"Craigie, R. & Bushman, F. D. H. I. V. DNA integration. Cold Spring Harb Perspect Med. 2, a006890 (2012).","journal-title":"Cold Spring Harb Perspect Med."},{"key":"BFsrep25375_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2217\/fvl.12.56","volume":"7","author":"R Craigie","year":"2012","unstructured":"Craigie, R. The molecular biology of HIV integrase. Future Virol. 7, 679\u201389 (2012).","journal-title":"Future Virol."},{"key":"BFsrep25375_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/COH.0b013e3283567309","volume":"7","author":"DJ Hazuda","year":"2012","unstructured":"Hazuda, D. J. HIV integrase as a target for antiretroviral therapy. Curr Opin HIV AIDS 7, 383\u201389 (2012).","journal-title":"Curr Opin HIV AIDS"},{"key":"BFsrep25375_CR4","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1093\/jac\/dku095","volume":"69","author":"I Malet","year":"2014","unstructured":"Malet, I. et al. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J Antimicrob Chemoth. 69, 2118\u20132112 (2014).","journal-title":"J Antimicrob Chemoth."},{"key":"BFsrep25375_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/jac\/dkp153","volume":"64","author":"N Sichtig","year":"2009","unstructured":"Sichtig, N. et al. Evolution of raltegravir resistance during therapy. J Antimicrob Chemother. 64, 25\u201332 (2009).","journal-title":"J Antimicrob Chemother."},{"key":"BFsrep25375_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMoa0708975","volume":"359","author":"RT Steigbigel","year":"2008","unstructured":"Steigbigel, R. T. et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 359, 339\u201354 (2008).","journal-title":"N Engl J Med."},{"key":"BFsrep25375_CR7","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1097\/QAD.0b013e3283473599","volume":"25","author":"M M\u00e9tifiot","year":"2011","unstructured":"M\u00e9tifiot, M. et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 25, 1175\u201378 (2011).","journal-title":"AIDS"},{"key":"BFsrep25375_CR8","doi-asserted-by":"publisher","first-page":"8316","DOI":"10.1073\/pnas.0700781104","volume":"104","author":"Z Hayouka","year":"2007","unstructured":"Hayouka, Z. et al. Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium. Proc Natl Acad Sci USA 104, 8316\u201321 (2007).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep25375_CR9","first-page":"1","volume":"389","author":"L Feng","year":"2015","unstructured":"Feng, L., Larue, R. C., Slaughter, A., Kessl, J. J. & Kvaratskhelia, M. Curr Top Microbiol Immunol 389, 1\u201327 (2015).","journal-title":"Curr Top Microbiol Immunol"},{"key":"BFsrep25375_CR10","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1177\/1087057111436343","volume":"17","author":"J Demeulemeester","year":"2012","unstructured":"Demeulemeester, J., Tintori, C., Botta, M., Debyser, Z. & Christ, F. Development of an AlphaScreen-based HIV-1 integrase dimerization assay for discovery of novel allosteric inhibitors. J Biomol Screen. 17, 618\u201328 (2012).","journal-title":"J Biomol Screen."},{"key":"BFsrep25375_CR11","doi-asserted-by":"publisher","first-page":"33580","DOI":"10.1074\/jbc.M109.040121","volume":"284","author":"M Tsiang","year":"2009","unstructured":"Tsiang, M. et al. Affinities between the binding partners of the HIV-1 integrase dimer-lens epithelium-derived growth factor (IN dimer-LEDGF) complex. J Bio Chem. 284, 33580\u201399 (2009).","journal-title":"J Bio Chem."},{"key":"BFsrep25375_CR12","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/4243","volume":"16","author":"A Krantz","year":"1998","unstructured":"Krantz, A. Protein-site targeting. Diversification of the drug discovery process. Nat Biotechnol. 16, 1294 (1998).","journal-title":"Nat Biotechnol."},{"key":"BFsrep25375_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.drudis.2013.11.005","volume":"19","author":"G Jin","year":"2014","unstructured":"Jin, G. & Wong, S. T. C. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 19, 637\u201344 (2014).","journal-title":"Drug Discov Today"},{"key":"BFsrep25375_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 3, 673\u201383 (2004).","journal-title":"Nat Rev Drug Discov."},{"key":"BFsrep25375_CR15","doi-asserted-by":"publisher","first-page":"22707","DOI":"10.1074\/jbc.M602198200","volume":"281","author":"E Guiot","year":"2006","unstructured":"Guiot, E. et al. Relationship between the Oligomeric Status of HIV-1 Integrase on DNA and Enzymatic Activity. J Biol Chem. 281, 22707\u201319 (2006).","journal-title":"J Biol Chem."},{"key":"BFsrep25375_CR16","doi-asserted-by":"publisher","first-page":"7712","DOI":"10.1074\/jbc.271.13.7712","volume":"271","author":"TM Jenkins","year":"1996","unstructured":"Jenkins, T. M., Engelman, A., Ghirlando, R. & Craigie, R. A. Soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization. J Biol Chem. 271, 7712\u201318 (1996).","journal-title":"J Biol Chem."},{"key":"BFsrep25375_CR17","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nchembio.2007.17","volume":"3","author":"J Inglese","year":"2007","unstructured":"Inglese, J. et al. High-throughput screening assays for the identification of chemical probes. Nat Chem Biol. 3, 466\u201379 (2007).","journal-title":"Nat Chem Biol."},{"key":"BFsrep25375_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nmeth.1351","volume":"6","author":"A Birmingham","year":"2009","unstructured":"Birmingham, A. et al. Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods 6, 569\u201375 (2009).","journal-title":"Nat Methods"},{"key":"BFsrep25375_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","volume":"4","author":"JH Zhang","year":"1999","unstructured":"Zhang, J. H., Chung, T. D. Y. & Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen., 4, 67\u201373 (1999).","journal-title":"J Biomol Screen."},{"key":"BFsrep25375_CR20","doi-asserted-by":"publisher","first-page":"13840","DOI":"10.1021\/bi011328n","volume":"40","author":"RG Maroun","year":"2001","unstructured":"Maroun, R. G. et al. Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers. Biochemistry 40, 13840\u201348 (2001).","journal-title":"Biochemistry"},{"key":"BFsrep25375_CR21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1177\/1087057113516861","volume":"19","author":"K Schorpp","year":"2014","unstructured":"Schorpp, K. et al. Identification of small-molecule frequent hitters from AlphaScreen high-throughput screens. J Biomol Screen. 19, 715\u201326 (2014).","journal-title":"J Biomol Screen."},{"key":"BFsrep25375_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1745-7254.2008.00748.x","volume":"29","author":"HQ He","year":"2008","unstructured":"He, H. Q. et al. A novel high-throughput format assay for HIV-1 integrase strand transfer reaction using magnetic beads. Acta Pharmacol Sin. 29, 397\u2013404 (2008).","journal-title":"Acta Pharmacol Sin."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep25375","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep25375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep25375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T14:48:38Z","timestamp":1672843718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep25375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,3]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,7,6]]}},"alternative-id":["BFsrep25375"],"URL":"https:\/\/doi.org\/10.1038\/srep25375","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,3]]},"assertion":[{"value":"12 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25375"}}